CytoDyn (CYDY) Gets a Hold Rating from H.C. Wainwright


In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CytoDyn (CYDY). The company’s shares closed last Tuesday at $2.73.

According to TipRanks.com, Chen is a 4-star analyst with an average return of 9.4% and a 37.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Aerpio Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for CytoDyn.

See today’s analyst top recommended stocks >>

Based on CytoDyn’s latest earnings release for the quarter ending August 31, the company reported a quarterly GAAP net loss of $30.83 million. In comparison, last year the company had a GAAP net loss of $16.16 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts